Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a Meta-analysis

Wang, Shi-Dan; Zhang, Guoming

doi:10.18240/ijo.2020.05.17

Cited by 29 publications

(28 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent meta-analysis by Popovic et al (32) comparing IVI and laser photocoagulation showed that the need for repeat treatment was less common after laser photocoagulation, astigmatism and the need for surgery were lower after IVI, and there was no significant difference between IVI and laser photocoagulation in terms of vision, safety, and disease regression times. In a study showing that IVI therapy was at least as effective as laser photocoagulation and that the risk of complications and retreatment was lower, the degree of myopia was found to be higher in APROP patients compared to type 1 ROP patients (33)(34)(35).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Infants with Retinopathy of Prematurity Treated with Intravitreal Bevacizumab

Özdemir¹,

Ceran²,

Akin³

et al. 2022

Turkish Journal of Pediatric Disease

View full text Add to dashboard Cite

Objective: To evaluate the systemic and local effects and side effects of intravitreal bevacizumab injection in preterm infants with aggressive posterior retinopathy of prematurity.Material and Methods: A total of 16 patients were included in this single-center observational cohort study between June 2020 and March 2021. The clinical, laboratory, and radiological findings before and after intravitreal injection of 0.3 mg bevacizumab were recorded for a total of 32 eyes. Results:The patients' mean gestational age at birth was 25±0.38 weeks and their mean birth weight was 695±119.2 g. None of the patients developed complications such as local vitreous hemorrhage or endophthalmitis secondary to intravitreal injection administered at a postmenstrual age of 34 weeks, and none required repeated injections. There was no increase in the rate of intraventricular hemorrhage after injection. There was no statistically significant difference in the patients' laboratory parameters, blood pressure values, or systemic findings before and after treatment. Conclusion:Although no systemic or local side effects were observed in patients treated with intravitreal bevacizumab injection in this study, patients should be monitored closely for systemic hypertension, intraventricular hemorrhage, and hypotension. More detailed studies are needed to evaluate later neurodevelopmental outcomes compared to other treatment options.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of Infants with Retinopathy of Prematurity Treated with Intravitreal Bevacizumab

Özdemir¹,

Ceran²,

Akin³

et al. 2022

Turkish Journal of Pediatric Disease

View full text Add to dashboard Cite

show abstract

“…The survival rate of premature babies with ROP is improving due improved medical treatment, including the use of anti-VEGF drugs and laser-based therapies. Wang et al reported the use of anti-VEGF drugs for treatment of ROP [ 21 ]. Additionally, Ekinci et al have suggested comparing the efficacy between intravitreal aflibercept and laser photocoagulation in ROP treatment [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

Cytochrome P450 2J2 inhibits the proliferation and angiogenesis of retinal vascular endothelial cells by regulating the Notch signaling pathway in a hypoxia-induced retinopathy model

et al. 2021

View full text Add to dashboard Cite

Retinopathy of Prematurity (ROP), a type of retinal neovascularization in premature infants, has become a serious problem that drastically affects the quality of life of premature infants. ROP is associated with angiogenesis and neovascularization. Here, we aimed to explain the function and latent roles of Cytochrome P450 2J2 (CYP2J2) in hypoxia-induced retinopathy in retinal vascular endothelial cells (HRVECs). HRVECs were stimulated with hypoxia for 24 h to establish an in vitro retinopathy model. Cell viability and migration were evaluated using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) and Transwell assays, respectively. Protein and gene expression was determined by reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) and Western blot analysis. We observed that pcDNA3.1(+)-CYP2J2 promoted CYP2J2 and Jagged1 expression, while Dll4 was down-regulated in hypoxia-stimulated HRVECs. Additionally, pcDNA3.1(+)-CYP2J2 inhibited HRVEC viability, reduced PCNA expression, and inhibited the migration of HRVECs. Further, the Notch pathway was inhibited in the Hypoxia+pcDNA3.1(+)-CYP2J2 group. Opposite results were observed upon Terfenadone treatment in hypoxia induced HRVECs. Finally, our findings further verified that DAPT promotes the effects of CYP2J2 on cell viability, migration, and Notch signaling in hypoxia-induced HRVECs, while EDTA reversed the inhibitory effects of CYP2J2 on hypoxia-induced HRVECs. In conclusions, CYP2J2 was found to inhibit the viability and angiogenesis of HRVECs by inhibiting Notch signaling in a hypoxia-induced retinopathy model.

show abstract

“…Le taux d'échec est inférieur à 9 % [31] dans les 9 semaines post-traitement. La complication la plus sévère à long-terme est le développement d'une myopie, dont le degré semble corrélé au nombre d'impacts reçus et à l'extension de la ROP [32]. Ses indications sont bien établies et reposent sur les résultats de deux essais thérapeutiques majeurs, CRYO-ROP [33] et ETROP [31].…”

Section: Modalités De Traitement Photocoagulation Par Laserunclassified

“…méta-analyse récente suggère une efficacité similaire au traitement laser [32]. Mais de nombreuses interrogations persistent, notamment concernant la posologie optimale et la sécurité à long terme.…”

Section: Synthèse Revuesunclassified

“…Récemment, l'étude Rainbow [37], critiquée elle aussi pour ses limites méthodologiques, a montré une tendance (non significative) à la supériorité du traitement par le ranibizumab 8 (0,2 mg) sur celui par laser dans les ROP en zone 1, stade 1+, 2+, 3, ou 3+, ou en zone 2 stade 3+, ou ROP agressive postérieure (Figure 2), ainsi qu'une moindre incidence de résultats structuraux défavorables à court terme. Un avantage potentiel des anticorps anti-VEGF, par rapport au laser, serait la moindre incidence de myopie à long-terme [32], L'incertitude sur les effets systémiques potentiels à long terme des anticorps anti-VEGF doit être prise en compte lors de la décision thérapeutique. En effet, il existe un passage dans la circulation sanguine de ces anticorps après IVT chez le prématuré.…”

Section: Synthèse Revuesunclassified

See 1 more Smart Citation

Rétinopathie du prématuré : de la prévention au traitement

et al. 2020

View full text Add to dashboard Cite

La rétinopathie du prématuré (ROP) est la principale cause évitable de cécité infantile. Son incidence augmente avec la survie de nouveau-nés extrêmement prématurés. La ROP est une pathologie multi-factorielle du développement de la rétine et du réseau vasculaire rétinien, impliquant des facteurs oxygéno-dépendants et nutritionnels. La multiplicité des facteurs participant à la survenue de la ROP plaide en faveur de stratégies préventives complémentaires et synergiques, telles que le contrôle rigoureux de l’oxygénothérapie, l’optimisation des apports nutritionnels et de la croissance post-natale, l’allaitement maternel, un apport suffisant en AGPI-ω-3 et le contrôle des épisodes hyperglycémiques liés à la prématurité. La ROP nécessite une prise en charge multidisciplinaire, qui inclut un dépistage systématique, un traitement adapté et un suivi à long terme. Les modalités actuelles de dépistage font appel à une caméra grand-champ, permettant également un dépistage par télémédecine. Le traitement de référence de la ROP demeure la photocoagulation au laser. Il peut être associé à des injections intravitréennes d’anticorps anti-VEGF, en cours d’évaluation, ou à la chirurgie pour les stades avancés.

show abstract

Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a Meta-analysis

Cited by 29 publications

References 37 publications

Evaluation of Infants with Retinopathy of Prematurity Treated with Intravitreal Bevacizumab

Evaluation of Infants with Retinopathy of Prematurity Treated with Intravitreal Bevacizumab

Cytochrome P450 2J2 inhibits the proliferation and angiogenesis of retinal vascular endothelial cells by regulating the Notch signaling pathway in a hypoxia-induced retinopathy model

Rétinopathie du prématuré : de la prévention au traitement

Contact Info

Product

Resources

About